Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

08.01.2024 - ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy (GA) to Initiate Mid-2024; First ... Seite 1

Related Keywords

Brisbane ,Queensland ,Australia , ,Nasdaq ,Annexon Inc ,Clinical Proof Of Concept Study ,Kind Oral Small Molecule Inhibitor ,Classical Pathway ,First Half ,Financing Extends Operating Runway ,Second Quarter ,Douglas Love ,Report Pivotal Data ,Annexon Chart ,Nnexon Kurs ,Nnexon Aktie ,